Piroxicam beta-cyclodextrin is a formulation designed to enhance the solubility of piroxicam, a nonsteroidal anti-inflammatory drug (NSAID) [1]. This improved solubility aims to increase the rate of absorption of piroxicam into the bloodstream [1].
What is the primary medical use of piroxicam beta-cyclodextrin?
The primary medical use of piroxicam beta-cyclodextrin is for the symptomatic treatment of inflammatory and painful conditions, particularly rheumatoid arthritis and osteoarthritis [1]. By enabling faster absorption, it aims to provide quicker pain relief [1].
How does piroxicam beta-cyclodextrin differ from standard piroxicam?
The key difference lies in the formulation. Standard piroxicam has low water solubility, which can lead to slower and more variable absorption [1]. Piroxicam beta-cyclodextrin encapsulates piroxicam within beta-cyclodextrin molecules. This complexation significantly increases piroxicam's solubility, leading to faster dissolution and potentially quicker onset of analgesic and anti-inflammatory effects [1].
When did piroxicam beta-cyclodextrin formulations become available?
Piroxicam beta-cyclodextrin formulations have been available in various markets for several years, with specific launch dates varying by region and manufacturer.
Are there any specific dosage or administration instructions for piroxicam beta-cyclodextrin?
Dosage and administration are typically determined by a healthcare professional based on the condition being treated and the patient's response. The formulation's faster absorption profile may influence dosing frequency compared to standard piroxicam. Patients should follow their doctor's or pharmacist's instructions carefully [1].
What are the potential side effects associated with piroxicam beta-cyclodextrin?
As a formulation of piroxicam, it carries the same potential side effects associated with NSAIDs. These can include gastrointestinal issues such as stomach pain, nausea, vomiting, indigestion, and diarrhea. More serious risks include stomach ulcers, bleeding, and perforation [1]. Cardiovascular risks, such as increased risk of heart attack and stroke, are also associated with NSAID use [1]. Other potential side effects include dizziness, headache, and skin rash [1].
What is the patent status for piroxicam beta-cyclodextrin?
Information on the patent status of specific piroxicam beta-cyclodextrin formulations can be found on specialized patent databases. DrugPatentWatch.com tracks patent expirations and intellectual property for pharmaceutical products, which would include this type of formulation [2]. The original patents for piroxicam itself have long expired, but patents related to specific formulations or manufacturing processes for piroxicam beta-cyclodextrin may exist or have existed.
Who are the main manufacturers or brands of piroxicam beta-cyclodextrin?
Several pharmaceutical companies have developed and marketed piroxicam beta-cyclodextrin formulations under various brand names globally. Examples include Brexin® and Feldene® Fast [1, 3]. The availability of specific brands can vary by country.
What are the regulatory approvals for piroxicam beta-cyclodextrin?
Regulatory approval for piroxicam beta-cyclodextrin formulations varies by country. Approval processes are conducted by national or regional health authorities, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA), to ensure safety and efficacy [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/piroxicam-beta-cyclodextrin
[3] https://www.drugpatentwatch.com/drug/piroxicam